

NOVO NORDISK A S
Form 6-K
February 05, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 4, 2019

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Trading in Novo Nordisk shares by board members, executives and associated persons on 1 February 2019

Bagsværd, Denmark, 4 February 2019 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

As from 2004, members of Novo Nordisk's Executive Management and other members of the Senior Management Board have participated in a long-term share-based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. In 2015, seven current members of Executive Management (as well as other members of senior management) participated in the programme, where shares were allocated to the joint pool and the market value of the scheme was expensed in the accounts for 2015. In accordance with the principles of the programme, the Board of Directors of Novo Nordisk A/S on 31 January 2019 evaluated that the conditions for release of the joint pool of shares have been fulfilled. Accordingly, shares in the joint pool were transferred on 1 February 2019 to the seven current members of Executive Management as well as other current and former members of senior management. The reporting below reflects the transfer of such shares to the seven members of Executive Management.

As of 2007, a number of key employees below senior management level have also participated in a share-based programme with similar performance criteria as the programme for senior management. A programme was established for 2015, and two current Executive Vice Presidents have participated in this programme. In line with the programme for senior management, the Board of Directors of Novo Nordisk A/S on 31 January 2019 evaluated that the conditions for release of the shares have been fulfilled and the shares were transferred to the participants on 1 February 2019

accordingly. The reporting below reflects the transfer of such shares to two Executive Vice Presidents.

All employee representatives of the Board, the CEO and the Executive Vice Presidents have participated in a general employee share program in 2016 where 50 shares have been transferred to the participants on February 1, 2019.

- 1 Details of the person discharging managerial responsibilities/person closely associated
 - a) Name of the Board member/Executive/Associated Person Mette Bøjer Jensen
- 2 Reason for the notification
 - a) Position/status Member of the Board of Directors
(employee representative)
 - b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
 - a) Name Novo Nordisk A/S
 - b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
 - a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
 - b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	50 shares
 - d) Aggregated information
 - Aggregated volume 50 shares
 - Price DKK 0.00
 - e) Date of the transaction 1 February 2019
 - f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
 - a) Name of the Board member/Executive/Associated Person Anne Marie Kverneland
- 2 Reason for the notification
 - a) Position/status Member of the Board of Directors
(employee representative)
 - b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
 - a) Name Novo Nordisk A/S
 - b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
 - a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
Other transaction (transfer of shares
in accordance with a general
employee share programme
(restricted shares))
 - b) Nature of the transaction
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	50 shares
 - d) Aggregated information
 - Aggregated volume 50 shares
 - Price DKK 0.00
 - e) Date of the transaction 1 February 2019
 - f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
 - a) Name of the Board member/Executive/Associated Person Thomas Rantzau
- 2 Reason for the notification
 - a) Position/status Member of the Board of Directors
(employee representative)
 - b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
 - a) Name Novo Nordisk A/S
 - b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
 - a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
 - b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	50 shares
 - d) Aggregated information
 - Aggregated volume 50 shares
 - Price DKK 0.00
 - e) Date of the transaction 1 February 2019
 - f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
 - a) Name of the Board member/Executive/Associated Person Stig Strøbæk
- 2 Reason for the notification
 - a) Position/status Member of the Board of Directors
(employee representative)
 - b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
 - a) Name Novo Nordisk A/S
 - b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
 - a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
 - b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	50 shares
 - d) Aggregated information
 - Aggregated volume 50 shares
 - Price DKK 0.00
 - e) Date of the transaction 1 February 2019
 - f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen
- 2 Reason for the notification
- a) Position/status President and CEO
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with long-term incentive
programme)
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|---------------|
| | DKK 0.00 | 17,650 shares |
- d) Aggregated information
- Aggregated volume 17,650 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen
- 2 Reason for the notification
- a) Position/status President and CEO
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
 - a) Name of the Board member/Executive/Associated Person Jesper Brandgaard
- 2 Reason for the notification
 - a) Position/status EVP, Biopharm and Legal Affairs
 - b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
 - a) Name Novo Nordisk A/S
 - b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
 - a) Description of the financial instrument, type of instrument, Shares
 Identification code Novo Nordisk B DK0060534915
 - b) Nature of the transaction Other transaction (transfer of shares in
 accordance with long-term incentive
 programme)
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	21,768 shares
 - d) Aggregated information
 - Aggregated volume 21,768 shares
 - Price DKK 0.00
 - e) Date of the transaction 1 February 2019
 - f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Jesper Brandgaard
- 2 Reason for the notification
- a) Position/status EVP, Biopharm and Legal Affairs
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Jesper Brandgaard
- 2 Reason for the notification
- a) Position/status EVP, Biopharm and Legal Affairs
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Sale of shares
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|------------|---------------|
| | DKK 315.84 | 21,768 shares |
- d) Aggregated information
- Aggregated volume 21,768 shares
 - Price DKK 315.84
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
2	Reason for the notification	
a)	Position/status	EVP, International Operations
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
c)	Price(s) and volume(s)	
		Price(s) Volume(s)
		DKK 0.00 8,679 shares
d)	Aggregated information	
	- Aggregated volume	8,679 shares
	- Price	DKK 0.00
e)	Date of the transaction	
		1 February 2019
f)	Place of the transaction	
		Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar
- 2 Reason for the notification
- a) Position/status EVP, International Operations
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Lars Green

2 Reason for the notification

a) Position/status EVP, Business Services & Compliance

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, type of instrument, Shares

Identification code Novo Nordisk B DK0060534915

b) Nature of the transaction Other transaction (transfer of shares in accordance with long-term incentive programme)

c) Price(s) and volume(s)

Price(s) Volume(s)

DKK 0.00 8,679 shares

d) Aggregated information

- Aggregated volume 8,679 shares

- Price DKK 0.00

e) Date of the transaction 1 February 2019

f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Lars Green
- 2 Reason for the notification
- a) Position/status EVP, Business Services & Compliance
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Lars Green

2 Reason for the notification

a) Position/status EVP, Business Services & Compliance

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915

b) Nature of the transaction Sale of shares

c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 315.21	6,000 shares
DKK 317.38	627 shares
DKK 317.35	174 shares
DKK 317.35	419 shares
DKK 317.38	627 shares
DKK 317.38	627 shares
DKK 317.35	247 shares
DKK 317.35	8 shares

d) Aggregated information

- Aggregated volume 8,729 shares

- Price DKK 315.88

e) Date of the transaction 1 February 2019

f) Place of the transaction

Nasdaq Copenhagen

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen

2 Reason for the notification

a) Position/status EVP, chief financial officer

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, type of instrument, Shares
 Identification code Novo Nordisk B DK0060534915

b) Nature of the transaction Other transaction (transfer of shares in accordance with long-term incentive programme)

c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	7,763 shares

d) Aggregated information

- Aggregated volume 7,763 shares

- Price DKK 0.00

e) Date of the transaction 1 February 2019

f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen
- 2 Reason for the notification
- a) Position/status EVP, chief financial officer
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen

2 Reason for the notification

a) Position/status EVP, chief financial officer

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915

b) Nature of the transaction Sale of shares

c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 317.45	3,000 shares
DKK 317.40	3,000 shares
DKK 317.45	1,813 shares

d) Aggregated information

- Aggregated volume 7,813 shares

- Price DKK 317.43

e) Date of the transaction 1 February 2019

f) Place of the transaction Nasdaq Copenhagen

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Doug Langa
- 2 Reason for the notification
- a) Position/status EVP, North America Operations
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with long-term incentive
programme)
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|--------------|
| | DKK 0.00 | 2,600 shares |
- d) Aggregated information
- Aggregated volume 2,600 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Doug Langa
- 2 Reason for the notification
- a) Position/status EVP, North America Operations
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Doug Langa
- 2 Reason for the notification
- a) Position/status EVP, North America Operations
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Sale of shares
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|------------|------------|
| | DKK 315.80 | 910 shares |
- d) Aggregated information
- Aggregated volume 910 shares
 - Price DKK 315.80
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Nasdaq Copenhagen

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Camilla Sylvest

2 Reason for the notification

a) Position/status EVP, Commercial Strategy & Corporate Affairs

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, type of instrument, Shares
 Identification code Novo Nordisk B DK0060534915

b) Nature of the transaction Other transaction (transfer of shares in accordance with long-term incentive programme)

c) Price(s) and volume(s)

Price(s)	Volume(s)
DKK 0.00	2,500 shares

d) Aggregated information

- Aggregated volume	2,500 shares
- Price	DKK 0.00

e) Date of the transaction 1 February 2019

f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Camilla Sylvest
- 2 Reason for the notification
- a) Position/status EVP, Commercial Strategy & Corporate Affairs
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Mads Krogsgaard Thomsen						
2	Reason for the notification							
a)	Position/status	EVP, chief science officer						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares))						
c)	Price(s) and volume(s)	<table border="0"> <tr> <td></td> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td></td> <td>DKK 0.00</td> <td>50 shares</td> </tr> </table>		Price(s)	Volume(s)		DKK 0.00	50 shares
	Price(s)	Volume(s)						
	DKK 0.00	50 shares						
d)	Aggregated information							
-	Aggregated volume	50 shares						
-	Price	DKK 0.00						
e)	Date of the transaction	1 February 2019						
f)	Place of the transaction	Outside a trading venue						

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Mads Krogsgaard Thomsen
- 2 Reason for the notification
- a) Position/status EVP, chief science officer
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Sale of shares
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|------------|---------------|
| | DKK 315.71 | 22,178 shares |
- d) Aggregated information
- Aggregated volume 22,178 shares
 - Price DKK 315.71
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Nasdaq Copenhagen

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Signe Krogsgaard Gudnason
- 2 Reason for the notification
- a) Position/status Associated to Mads Krogsgaard Thomsen, EVP, Chief Science Officer
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Purchase of shares
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|------------|------------|
| | DKK 315.71 | 205 shares |
- d) Aggregated information
- Aggregated volume 205 shares
 - Price DKK 315.71
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Nasdaq Copenhagen

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Sebastian Krogsgaard Gudnason
- 2 Reason for the notification
- a) Position/status Associated to Mads Krogsgaard Thomsen, EVP, Chief Science Officer
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Purchase of shares
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|------------|------------|
| | DKK 315.71 | 205 shares |
- d) Aggregated information
- Aggregated volume 205 shares
 - Price DKK 315.71
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Nasdaq Copenhagen

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Henrik Wulff
- 2 Reason for the notification
- a) Position/status EVP, Product Supply
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with long-term incentive
programme)
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|---------------|
| | DKK 0.00 | 11,687 shares |
- d) Aggregated information
- Aggregated volume 11,687 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

- 1 Details of the person discharging managerial responsibilities/person closely associated
- a) Name of the Board member/Executive/Associated Person Henrik Wulff
- 2 Reason for the notification
- a) Position/status EVP, Product Supply
- b) Initial notification/Amendment Initial notification
- 3 Details of the issuer
- a) Name Novo Nordisk A/S
- b) LEI 549300DAQ1CVT6CXN342
- 4 Details of the transaction(s)
- a) Description of the financial instrument, type of instrument, Shares
Identification code Novo Nordisk B DK0060534915
- b) Nature of the transaction Other transaction (transfer of shares in
accordance with a general employee share
programme (restricted shares))
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | DKK 0.00 | 50 shares |
- d) Aggregated information
- Aggregated volume 50 shares
 - Price DKK 0.00
- e) Date of the transaction 1 February 2019
- f) Place of the transaction Outside a trading venue

Definitions and background information:

Publication

Publication shall take place no later than three working days after the trading by board members, executives or their associated persons. Publication is only required when the total amount of transactions of a specific board member/executive or his/her associated persons in any one calendar year has reached EUR 20,000 (calculated individually).

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined as brothers, sisters, parents, grandparents, children, grandchildren, cousins etc. who have shared the same household with a board member or executive for a period of at least one year on the date of the given transaction and 4) any legal persons, trust, or partnership, the managerial responsibilities of which are discharged by a board member/executive or by a person referred to in items 1)-3) above, or which is directly or indirectly controlled by such a person, or which is set up for the benefit of such a person, or the economic interests of which are substantially equivalent to those of such a person.

What is trading/transaction?

Trading is any kind of transaction, including shares and share related securities purchased or otherwise acquired, sold or otherwise disposed, gifts, mortgages, heritage and grants, allotments and exercise of options.

What is financial instrument and ID code?

Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.

What is date and place of transaction?

Edgar Filing: NOVO NORDISK A S - Form 6-K

Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock Exchange.

What is the volume and price of transaction and aggregated information?

The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. In case of a single transaction the price is the price of that single transaction. In case of multiple transactions, when the transactions relates to the same financial instrument, are of the same nature, are executed on the same day and are executed on the same place, the volume must be aggregated. The price of the aggregated transactions is the weighted average price.

The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Mette Kruse Danielsen	+45 4442 3883	krsp@novonordisk.com
Ken Inchausti (US)	+1 609 240 9429	kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen	+45 3075 9085	phak@novonordisk.com
Anders Mikkelsen	+45 3079 4461	armk@novonordisk.com
Valdemar Borum Svarrer	+45 3079 0301	jvls@novonordisk.com
Kristoffer Due Berg	+45 3079 2849	krdb@novonordisk.com
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com

Novo Nordisk A/S	Novo Allé	Telephone:	Internet:
	2880 Bagsværd	+45 4444 8888	www.novonordisk.com
Investor Relations	Denmark		CVR no:
			24 25 67 90

Company announcement No 7 / 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 4, 2019

Lars Fruergaard Jørgensen

Chief Executive Officer